A better understanding of the mechanisms of the complex communication network of the TME via IL-33 in tumor–stromal signaling, on a cellular and molecular basis, may provide a new potential therapeutic target for the treatment of HNSCCs. The gene discussed is IL33; the disease is neoplasm.